Latest Post

China’s drug price deregulation

China’s drug price deregulation

Last month, media reports surfaced over a missive that China’s central pricing authority had issued to provincial pricing authorities during an internal meeting, and which was leaked to the press. The statement detailed one of the biggest drug pricing changes in China in years – the widescale liberalisation of pharmaceutical prices. While the finer details … Continue reading

Recent Posts

Pages

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter

Follow

Get every new post delivered to your Inbox.

Join 332 other followers